Scientists Hail New Antibiotic that can Kill Drug-Resistant Bacteria

Technology News ,Medical Science :- Scientists have found a brand-new kind of antibiotic that seems to be effective against one of the three bacteria that pose a major threat to human health due to their high drug resistance. This breakthrough involves a drug called Zosurabalpin, which successfully fought against Carbapenem-resistant Acinetobacter baumannii (Crab) in mouse models of pneumonia and sepsis. Crab is categorized as a top-priority pathogen by the World Health Organization, alongside two other drug-resistant bacteria.

Dr. Andrew Edwards from Imperial College London, not involved in the study, emphasized the significance of this discovery. Crab causes infections in hospitals, especially in ventilator-dependent individuals. Its resistance to multiple antibiotics makes treatment challenging. Developing new treatments against Crab has been tough, but Zosurabalpin shows promise by overcoming the bacterium outer cell layer barrier.

Antibiotic-resistant infections, especially those caused by Gram-negative bacteria, are a pressing threat to human health. Gram-negative bacteria have an outer shell with lipopolysaccharide (LPS), protecting them from antibiotics and immune system attacks. Roche Pharma Research and Early Development in Switzerland created Zosurabalpin, a drug identified for blocking A baumannii growth. Through experiments at Harvard University, researchers discovered that the drug prevents LPS transport, effectively killing the bacterium.

While Zosurabalpin alone won"t completely solve the problem of antibiotic-resistant infections, it opens doors for future efforts targeting similar transport systems in other bacteria. Another antibiotic in development, murepavadin, also targets LPS transport but through a different mechanism, potentially expanding the approach to combat other antibiotic-resistant bacteria.

Despite these advancements, transitioning from animal studies to human trials can be challenging. Simultaneously, the UK science, innovation, and technology committee advocate exploring bacteriophages, viruses that kill bacteria, as an alternative to antibiotics. However, the development of phage therapies faces obstacles, requiring specific standards for clinical trials, which, in turn, depend on successful clinical trials. The committee suggests considering the establishment of a facility in the West Midlands to support the production of bacteriophages.